Skip to content
Medical Health Aged Care

IMPROVING DEEP SLEEP MAY PREVENT DEMENTIA, STUDY FINDS

Monash University 2 mins read

As little as 1 per cent reduction in deep sleep per year for people over 60 years of age translates into a 27 per cent increased risk of dementia, according to a Monash study which suggests that enhancing or maintaining deep sleep, also known as slow wave sleep, in older years could stave off dementia.

The study, led by Associate Professor Matthew Pase, from the Monash School of Psychological Sciences and the Turner Institute for Brain and Mental Health in Melbourne, Australia, and published today in JAMA Neurology, looked at 346 participants, over 60 years of age, enrolled in the Framingham Heart Study who completed two overnight sleep studies in the time periods 1995 to 1998 and 2001 to 2003, with an average of five years between the two studies.

These participants were then carefully followed for dementia from the time of the second sleep study through to 2018. The researchers found, on average, that the amount of deep sleep declined between the two studies, indicating slow wave sleep loss with ageing. Over the next 17 years of follow-up, there were 52 cases of dementia. Even adjusting for age, sex, cohort, genetic factors, smoking status, sleeping medication use, antidepressant use, and anxiolytic use, each percentage decrease in deep sleep each year was associated with a 27 per cent increase in the risk of dementia.

“Slow-wave sleep, or deep sleep, supports the ageing brain in many ways, and we know that sleep augments the clearance of metabolic waste from the brain, including facilitating the clearance of proteins that aggregate in Alzheimer’s disease,” Associate Professor Pase said.

“However, to date we have been unsure of the role of slow-wave sleep in the development of dementia. Our findings suggest that slow wave sleep loss may be a modifiable dementia risk factor.”

Associate Professor Pase said that the Framingham Heart Study is a unique community-based cohort with repeated overnight polysomnographic (PSG) sleep studies and uninterrupted surveillance for incident dementia.

“We used these to examine how slow-wave sleep changed with ageing and whether changes in slow-wave sleep percentage were associated with the risk of later-life dementia up to 17 years later,” he said.

“We also examined whether genetic risk for Alzheimer’s Disease or brain volumes suggestive of early neurodegeneration were associated with a reduction in slow-wave sleep. We found that a genetic risk factor for Alzheimer’s disease, but not brain volume, was associated with accelerated declines in slow wave sleep.”

 


Contact details:

Tania Ewing

tania.ewing1@monash.edu

0408378422

More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17
Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.